Full-Year Ended December 31, 2026 Acquired IPR&D and Milestones Expense Adjusted Diluted EPS Range Acquired IPR&D and Milestones Expense Adjusted Diluted EPS Range Low High Low High Previously announced guidance excluding Q2 2026 acquired IPR&D and milestones expense $ — $ $ $ $ $ Q2 2026 acquired IPR&D and milestones expense (0.17) (0.17) Guidance including Q2 2026 acquired IPR&D and milestones expense a $ $ $ $ 1,035 $ $ a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the second quarter of 2026, as both cannot be reliably forecasted.

· Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases · Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients with atopic dermatitis · Apogee’s pipeline also includes combinations of its novel antibodies; APG273, a potential best-in-category long-acting combination targeting IL-13 and thymic stromal lymphopoietin (TSLP), is being developed in asthma · Apogee shareholders to receive $135.11 per share in cash, for a total equity value of approximately $10.9 billion · AbbVie to hold investor conference call today, June 22, at 8:00 a.m.